MX2017016337A - Tratamiento de carcinoma de linea media nut. - Google Patents

Tratamiento de carcinoma de linea media nut.

Info

Publication number
MX2017016337A
MX2017016337A MX2017016337A MX2017016337A MX2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A
Authority
MX
Mexico
Prior art keywords
nut line
carcinoma treatment
bromodomain inhibitor
medium nut
nmc
Prior art date
Application number
MX2017016337A
Other languages
English (en)
Spanish (es)
Inventor
B Landau Steven
H Kagey Michael
Original Assignee
Tensha Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tensha Therapeutics Inc filed Critical Tensha Therapeutics Inc
Publication of MX2017016337A publication Critical patent/MX2017016337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2017016337A 2015-06-26 2016-06-24 Tratamiento de carcinoma de linea media nut. MX2017016337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (1)

Publication Number Publication Date
MX2017016337A true MX2017016337A (es) 2018-11-22

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016337A MX2017016337A (es) 2015-06-26 2016-06-24 Tratamiento de carcinoma de linea media nut.

Country Status (14)

Country Link
US (1) US20180193350A1 (enExample)
EP (1) EP3314005A1 (enExample)
JP (1) JP2018520124A (enExample)
KR (1) KR20180035785A (enExample)
CN (1) CN107787227A (enExample)
AR (1) AR105124A1 (enExample)
AU (1) AU2016283020A1 (enExample)
BR (1) BR112017028178A2 (enExample)
CA (1) CA2989313A1 (enExample)
HK (1) HK1252062A1 (enExample)
IL (1) IL256186A (enExample)
MA (1) MA42249A (enExample)
MX (1) MX2017016337A (enExample)
WO (1) WO2016210275A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
EP4629984A1 (en) * 2022-12-06 2025-10-15 BioVentures, LLC Development of potent dual hdac/brd4 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN101910182B (zh) * 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AU2010317096B2 (en) 2009-11-05 2015-03-26 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
EP2585465B1 (en) 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia

Also Published As

Publication number Publication date
MA42249A (fr) 2018-05-02
WO2016210275A1 (en) 2016-12-29
AR105124A1 (es) 2017-09-06
KR20180035785A (ko) 2018-04-06
AU2016283020A1 (en) 2018-01-04
US20180193350A1 (en) 2018-07-12
IL256186A (en) 2018-02-28
CN107787227A (zh) 2018-03-09
JP2018520124A (ja) 2018-07-26
BR112017028178A2 (en) 2018-08-28
HK1252062A1 (zh) 2019-05-10
EP3314005A1 (en) 2018-05-02
CA2989313A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
MX2017005555A (es) Inhibidores del bromodominio.
MX2018003824A (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control.
EA201790398A1 (ru) Способы лечения заболевания печени
MX2017016868A (es) Composiciones y metods para inhibir actividad de arginasa.
CL2016000959A1 (es) Adenovirus oncolíticos armados con genes heterologos
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EA201690987A1 (ru) Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CO2017012988A2 (es) Agentes, usos y métodos para el tratamiento
EA201790845A1 (ru) Способ лечения рака
MX2018001737A (es) Mecanismo de resistencia a inhibidores de bromodominio bet.
BR112017000852A2 (pt) ?aparelho e método para gerar um sinal melhorado utilizando enchimento de ruído independente?.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
ECSP20082339A (es) Moduladores de la expresión de apol1
MX382996B (es) Inhibidores de pcna
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
EP4324477A3 (en) Oxabicycloheptanes for modulation of immune response
AR117094A1 (es) Moduladores de expresión irf5
EA201890118A1 (ru) Способ обработки молока
WO2015112809A3 (en) Nsd3 inhibitors for treatment of cancers